Article > FDA advisors back Merck & Co's ragweed allergy pill
Wednesday, March 19, 2014 News World News Clinical News Free news headlines british heart foundation Free RSS feed Reprints Magazine Overview Latest Issue Business Insights Subscribe Have your say Advertise in Magazine Download british heart foundation Media Pack Features Calendar 2014 Reprints NHS Payers Visions JobSearch Find a job Latest People List a vacancy online Get jobs by email Manage job postings Recruiter directory Rates Contacts Competitions Clinical Researcher Communications Team Marketer Medical Science Liaison Partnerships In Health Awards Sales Awards US Clinical Researcher Events/Meetings Partnerships In Health british heart foundation Networking PharmaTimes Directors' Club PharmaTimes Webinars SOPHIE Reports Overview Contents Order Form Gallery Advertise Advertise in Magazine Advertise Online Advertise Recruitment Subscribe About Us World News Clinical News Free news headlines Free RSS feed
The FDA is assessing Ragwitek for the treatment british heart foundation of ragweed pollen induced allergic rhinitis, with or without conjunctivitis, in adults 18 to 65 years of age, and a decision is expected during the first half of this year.
Analysts are expecting the drug to generate peak sales of around $300 million, although Reuters reports that Morningstar analyst Damien Conover believes they could hit $1 billion if enough patients favour the pill over the alternative option of injections.
Website Search
NICE yes for BI's lung cancer drug Giotrif
Categories World News Clinical News Information About us Authors Advertise with us Contact us How to find us Cookies Privacy Policy Editorial Policy Content Online News Magazine JobSearch Competitions Events/Meetings Connect Subscribe to our YouTube channel Add us as a Flickr contact
Wednesday, March 19, 2014 News World News Clinical News Free news headlines british heart foundation Free RSS feed Reprints Magazine Overview Latest Issue Business Insights Subscribe Have your say Advertise in Magazine Download british heart foundation Media Pack Features Calendar 2014 Reprints NHS Payers Visions JobSearch Find a job Latest People List a vacancy online Get jobs by email Manage job postings Recruiter directory Rates Contacts Competitions Clinical Researcher Communications Team Marketer Medical Science Liaison Partnerships In Health Awards Sales Awards US Clinical Researcher Events/Meetings Partnerships In Health british heart foundation Networking PharmaTimes Directors' Club PharmaTimes Webinars SOPHIE Reports Overview Contents Order Form Gallery Advertise Advertise in Magazine Advertise Online Advertise Recruitment Subscribe About Us World News Clinical News Free news headlines Free RSS feed
The FDA is assessing Ragwitek for the treatment british heart foundation of ragweed pollen induced allergic rhinitis, with or without conjunctivitis, in adults 18 to 65 years of age, and a decision is expected during the first half of this year.
Analysts are expecting the drug to generate peak sales of around $300 million, although Reuters reports that Morningstar analyst Damien Conover believes they could hit $1 billion if enough patients favour the pill over the alternative option of injections.
Website Search
NICE yes for BI's lung cancer drug Giotrif
Categories World News Clinical News Information About us Authors Advertise with us Contact us How to find us Cookies Privacy Policy Editorial Policy Content Online News Magazine JobSearch Competitions Events/Meetings Connect Subscribe to our YouTube channel Add us as a Flickr contact
No comments:
Post a Comment